Drugs / rhPDGF-BB
rhPDGF-BB
also known as
rhPDGF · Recombinant human platelet derived growth factor B · Recombinant human platelet derived growth factor BB · recombinant human platelet-derived growth factor
Protein / enzyme biologic targets PDGFRB via activation
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 25 trials | ||||||
| Phase 2 | NCT06634030 | Apr 2025 → Jul 2026 | — | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT06632418 | Nov 2024 → Jul 2026 overdue | anal fistula | Alexander Hawkins | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06162832 | Jan → Jul 2024 | periodontitis | Autonomous University of Nuevo León | Unknown | No outcome recorded |
| Phase 2 | NCT03037970 | Jan → Aug 2017 | ulcer of lower limbs | Lynch Biologics LLC | Unknown | No outcome recorded |
| Phase 2 | NCT01746420 | Dec 2012 → Oct 2014 | epicondylitis | BioMimetic Therapeutics | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00496847 | Aug 2007 → Aug 2008 | periodontal disorder | Virchow Group | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01530126 | Jan 2000 → Jan 2005 | periodontitis | University of Michigan | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rhPDGF-BB | “randomly assigned to rhPDGF-BB+β-TCP or β-TCP” PMID 21133980 ↗ Dec 2010 |
| Known as | Recombinant human platelet derived growth factor B | “Recombinant human platelet derived growth factor B (rhPDGF) is an FDA-approved protein-based therapeutic that signals through PDGFRβ to heal and regenerate cutaneous skin...” PMID 42396268 ↗ Jun 2026 |
| Known as | Recombinant human platelet derived growth factor BB | “Recombinant human platelet derived growth factor BB (rhPDGF)” PMID 42145621 ↗ May 2026 |
| Known as | recombinant human platelet-derived growth factor | “formulation containing recombinant human platelet-derived growth factor (rhPDGF-BB)” PMID 21133980 ↗ Dec 2010 |
| Known as | rhPDGF | “Recombinant human platelet derived growth factor B (rhPDGF) is an FDA-approved protein-based therapeutic that signals through PDGFRβ to heal and regenerate cutaneous skin...” PMID 42396268 ↗ Jun 20261“Recombinant human platelet derived growth factor BB (rhPDGF)” PMID 42145621 ↗ May 2026 |
| Action | Activate | “Pharmaceutical rhPDGF stimulation of PDGFRβ signaling promotes healing of skin, bone, and soft tissue.” PMID 42396268 ↗ Jun 2026 |
| Modality | Protein / enzyme biologic | “recombinant human platelet-derived growth factor” PMID 21133980 ↗ Dec 2010 |
| Route | Other | “Implantation of rhPDGF-BB” NCT00496847 ↗ |
| Target | PDGFRB | “Recombinant human platelet derived growth factor B (rhPDGF) is an FDA-approved protein-based therapeutic that signals through PDGFRβ to heal and regenerate cutaneous skin...” PMID 42396268 ↗ Jun 2026 |